# Sudarshan Jain

Type: Person

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/sudarshan-jain
Canonical HTML page: https://getbiobrief.com/entity/sudarshan-jain

## Recent coverage (1 stories)

### 200% US Tariff Threatens Indian Pharma's $50B+ US Generic Business
2026-08-01 11:15:43 · Sentiment: Negative · Impact: 6/10 · Sources: 2

The proposed US tariff on generic drugs—jumping to 200%—poses an existential threat to Indian pharmaceutical companies that have long dominated the American market. With margins razor-thin and a 4-5 year timeline needed to onshore production, industry leaders call the plan 'completely out of scope,' potentially forcing a major restructuring of global generic supply chains.
Full story: https://getbiobrief.com/story/indian-pharma-us-generic-tariff-200-percent-existential-threat

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.